Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Lilit Kazangyan represents investment banks as well as public and private companies in connection with a variety of domestic and international capital markets transactions, including initial public offerings, follow-on offerings, and high-yield and investment grade debt offerings. Ms. Kazangyan has significant experience in capital market financings by special purpose acquisition companies (SPACs). She also advises clients on general corporate matters, including securities laws compliance and corporate governance.

  • Represented the underwriters or issuer in various initial public offerings by SPACs, including those of Crescent Acquisition Corp, Tortoise Acquisition Corp., AMCI Acquisition Corp., ARYA Sciences Acquisition Corp., Leo Holdings Corp., Leisure Acquisition Corp., Osprey Energy Acquisition Corp., and Hennessy Capital Acquisition Corp. III. 
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of NeuroDerm Ltd., an Israel-based clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of Affimed N.V., a German-based clinical-stage biotechnology company focused on cancer immunotherapies.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of uniQure N.V., a Netherlands-based biotechnology company focused on gene therapies. 
  • Represented the underwriter in the initial public offering of Presbia PLC, an Ireland-based ophthalmic device company marketing an optical lens implant for treating presbyopia.
  • Represented the underwriters in the initial public offering of OncoMed Pharmaceuticals, Inc., a U.S.-based clinical-stage biopharmaceutical company developing antibody therapeutics targeting cancer stem cells.
  • Represented the underwriters or issuer in various follow-on equity offerings, including those of American Homes 4 Rent, Alcobra Ltd, and RedHill Biopharma Ltd.
  • Represented the underwriters or issuer in various follow-on debt offerings, including those of Senior Housing Properties Trust, Fidelity National Information Services, Inc., and O’Reilly Automotive, Inc.
  • Represented the sponsor in connection with the corporate finance aspects of acquisition transactions, including the $1.1 billion offering of high-yield notes and the $515 million offering of high-yield notes by two of its portfolio companies.
  • Represented the sales agent in various at-the-market offerings, including those of Adaptimmune Therapeutics plc, Corbus Pharmaceuticals Holdings, and Affimed N.V.